Month: January 2021

Artiva Biotherapeutics Announces Exclusive Global Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies

SAN DIEGO – (COMMERCIAL THREAD) – Artiva Biotherapeutics, Inc., an oncology company focused on the development and commercialization of primary allogeneic natural killer cell (NK) therapies to treat cancer, today announced that it has entered into a global collaboration exclusive and licensing agreement with Merck, known as MSD outside the United States and Canada, to […]

Back To Top